Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

As of Wednesday, January 07, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.40%, which has investors questioning if this is right time to sell.

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an investigational in vivo gene ...

As of Tuesday, January 13, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 7.83%, which has investors ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...

Celltrion reaffirmed its commitment to expanding both its biosimilar and novel drug pipelines as the Korean biopharmaceutical ...

Eureka Therapeutics, Inc., a clinical-stage biotechnology company advancing next-generation T-cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Celltrion outlines a blueprint for innovative drug development built on its antibody expertiseThe company highlights its ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...